Distilling Aspirations

Wholesale Distribution of Pharmaceuticals

We can help you with the following:


  • Contract Responsible Person (RP) / Deputy RP
  • Wholesale Distribution Authorisation – WDA Application
  • Good Distribution Practices (GDP) Compliance
  • GAP Analysis and Pre-Inspection Audits
  • GDP/ RP Training
  • Quality Systems – Build, maintain and the maintenance
  • Risk Assessment – Development and mitigation
  • Audit Planning – Delivery and Corrective Action

Find out more

Pharmacist and Pharmacies

We can help entrepreneurs gain their own pharmacy by aiding with:


  • NHS Contract Application
  • GPhC  Registration
  • Standard Operating Procedures (SOP)
  • Recruitment

Is your current pharmacy business at risk? We can consult you on:

  • Scoping gaps in the local pharmacy services provision?
  • “SWOT” analysis, bespoke marketing plan
  • Essential Services Support
  • GPhC Inspection preparation
  • Automation and Optimisation
  • Business Development

Find out more

Flexible Training and Workshops

We can meet all your training needs.

We have a range of courses that are highly inter-active and informative to meet all your pharmacy or wholesaler training requirements:


Find out more

Care Quality Commission

We can be your ‘one stop shop’ for CQC Registration and Compliance.  We can help with the following:


  • CQC registration
  • Documentation
  • Quality Management Systems
  • Pre Audit Analysis
  • Risk Profiling and Compliance
  • Bespoke Consultancy
  • Business improvement
  • Training and practical implementation

Find out more

Latest News

Devices law suits in the USA

Devices law suits in the USA – Litigation costs are rising. – Provision for litigation should be made in every device manufactures budget especially if they trade in the USA.   A large devices manufacturer of ostomy, continence, urology, and wound and skin care products—which has its U.S. headquarters in Minneapolis—had previously provisioned in their budget, 1.5 billion kroner (equivalent to $226.2 million) for law suits. (Related article: The Worst-Performing Medical Device Firms of 2015) however they have now found that their liabilities will be very much higher as their “Mesh” Litigation liabilities are set to  rise to an estimated $678.6 million. On top of the vaginal mesh cases the U.S. Justice Department is investigating into their sales practices. Vaginal mesh devices were developed and marketed to treat urinary incontinence. During 2008 through to 2010 reports of thousands of serious complications, including mesh erosion through the vagina, pain, infection, bleeding, pain during sexual intercourse (dyspareunia), organ perforation, and urinary problems were reported to the FDA. Several other companies have been sued as the use of these devices has resulted in litigation. (Related article:Top 7 Medtech Controversies) How do you manage your risks in your business, have you a disaster plan? Do you risk asses the products before launch?  How would you deal with this situation? Are the benefits of selling in the USA outweighing the potential losses? Is it time to re-assess your route the market? How do you train your sales team to deal with product complaints? Do they know how to report a PV complaint? More to the point who to report them... read more

Preventing Quality Issues: A Risk-Based Approach to Clinical Trial Monitoring

The traditional Gold Standard method of monitoring clinical trials involved on-site monitoring with 100% Source Data Verification (SDV) where Clinical Research Associates checked every data point of information reported. This may have been doable in the past when there were sufficient resources available to carry out 100% of every task needed.  It not only involved a high resource demand and cost but also showed a negligible effect on data quality[1]. The U.S Food and Drug Administration (FDA), European Medicines Association (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA) recommend a Risk-Based Monitoring (RBM) as a means of delivering a more efficient way of clinical trial monitoring.  RBM identifies that there is no single approach appropriate for every trial and encourages tailoring the monitoring plans to suit the needs of the trial involved.  This may therefore involve a reduced SDV, Targeted Monitoring and/or Triggered monitoring.  Deciding the level of monitoring needed for the trial is dependent on the Risk Assessment to be carried out at the beginning of the study. (A principle widely used across various sectors in identifying possible areas of concern within the business!)  The initial Risk Assessment helps identify and understand the source and cause of risks that could occur either during data collection or performance of processes.  Risks to be considered may include operational, regulatory, scientific or medical risks.  Assessing these will help create a monitoring plan and a RBM strategy which shows regulators that a robust process exists in identifying risks and possible actions needed to manage those risks.  The importance of documenting the monitoring plan after assessing these risks has been highlighted within the... read more

Are you happy with the results?

Over the years we have seen the world of pharmacy evolve from that of ‘Dispense and Supply’ to include an ever expanding range of clinical services, (medicines management, local enhanced services such as vascular checks, managing minor ailments and sexual healthcare amongst others). As the NHS in England adapts to new models of care under its ‘Five year forward view’ agenda[1], there is the promise of more to come.  At the centre of all this change has always been the needs of the patient; and at the forefront of the pharmacist’s (and other healthcare professional’s) actions must be the intention to provide all services in a safe manner and to an acceptable quality. According to the Health and Social care Information Centre the year 2014 saw an overwhelming 1,062.6 million prescription items dispensed, a 3.3% rise from the year before.  Previous research has also shown that, (on average); between 0.04% to 3% of items dispensed by community pharmacies contained a dispensing error of some sort.[2]  A staggering number for a growing prescription volume!  Most of us already know the only way to meet the demand of a growing workload and an evolving profession is to change our practise. So when I voiced my thoughts on how we should implement change, one can only imagine my surprise when I was faced with the statement, “this is how it’s always been done!”  To which I duly answered, “Are you happy with the results?” And if, my fellow pharmacists, the answer to that question is ‘NO’, then one must seriously consider the changes needed to attain the levels of excellence we strive... read more